Table 1 Cohorts’ clinical characteristics and rs2304166 genotypes’ distribution
From: GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients
Criteria | Natalizumab Responsive | Natalizumab Unresponsive | |
|---|---|---|---|
Exome cohort | n = 23 | n = 10 | |
Sex (Female/male) | 14 / 9 | 9 / 1 | |
MS type (RRMS/SPMS) | 19 / 4 | 6 / 4 | |
Age at natalizumab treatment (Average years) | 32.3 | 32.5 | |
Duration of natalizumab treatment (Average years) | 2.95 | 3 | |
EDSSa before/after natalizumab [Median (IQRb)] | 3 (2–4.5) / 3 (2–4) | 3.5 (2.5–6) / 6 (4.5–6.5) | |
GP6 rs2304166 genotypes | |||
GG | 7 | 0 | |
GC | 12 | 3 | |
CC | 4 | 7 | |
Replicate cohort | n = 67 | n = 19 | p-value |
Sex (Female/male) | 36 / 31 | 16 / 3 | 0.018 |
MS type (RRMS/SPMS) | 56 / 11 | 13 / 6 | 0.19 |
Age at natalizumab treatment (Average years) | 32.8 | 34.5 | 0.09 |
Duration of natalizumab treatment (Average years) | 3.17 | 3.25 | 0.66 |
EDSSa before/after natalizumab [Median (IQRb)] | 2.5 (2–4) / 2 (1.5–3) | 4.25 (2–6) / 6.5 (5.5–7) | < 0.001 |
GP6 rs2304166 genotypes | |||
GG | 20 | 1 | 0.0000027 |
GC | 37 | 4 | |
CC | 10 | 14 | |